Lipoprotein(a), or Lp(a), is a type of fat particle in the blood similar to LDL cholesterol. Elevated Lp(a) levels, often symptom-free, can significantly increase the risk of heart disease, stroke, and aortic stenosis. Researchers are actively seeking ways to lower Lp(a) to improve cardiovascular health, as high levels promote clotting and inflammation.
While lifestyle changes like diet and exercise have limited impact on Lp(a) levels, emerging therapies show potential in lowering Lp(a) and reducing the risk of cardiovascular events. Experts emphasize the importance of consulting healthcare providers to determine appropriate treatment strategies for managing heart health.
Novel RNA-based drugs are being developed to target the genetic instructions for Lp(a) production in the liver. These therapies could potentially lower Lp(a) levels significantly. Clinical trials are underway to assess the long-term safety and efficacy of these treatments.